Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM
Axsome Therapeutics (AXSM) Stock Price & Analysis
1,822 Followers
AXSM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$55.02 - $98.40
Previous Close$83.74
Volume680.37K
Average Volume (3M)702.28K
Market Cap
$3.98B
Enterprise Value$3.83B
Total Cash (Recent Filing)$331.44M
Total Debt (Recent Filing)$188.80M
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Aug 05, 2024EPS Estimate
-$1.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.38
Shares Outstanding47,495,827
10 Day Avg. Volume1,017,529
30 Day Avg. Volume702,279
Standard Deviation0.31
R-Squared0.04
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)45.18
Price to Sales (P/S)13.41
Price to Cash Flow (P/CF)-17.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue15.32
Enterprise Value/Gross Profit15.68
Enterprise Value/Ebitda-13.89
Forecast
1Y Price Target
$121.11Price Target Upside47.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Axsome Therapeutics News
Bulls Say, Bears Say
Bulls Say
Adherence RatesRecent KOL feedback received by Axsome suggests Auvelity adherence of ~2x the levels historically observed with SSRI treatments.
Prescription GrowthAuvelity achieved ~18K new patient starts and >3.5K prescribers wrote initial prescriptions for Auvelity in 1Q24.
Sales PerformanceThrough the initial six quarters of its launch, Auvelity has generated ~$189M in sales.
Bears Say
Decreased SalesAuvelity scripts decreased week/week.
Exclusion From FormulariesSeveral large PBMs (CVS Health and Cigna) have excluded Auvelity from their formularies, likely accounting for a large chunk of non-covered commercial lives.
Revenue Recognition ConcernsA short report raised concerns regarding revenue recognition of Auvelity sales and alleged improper selling practices.
---
Ownership Overview
0.51% Insiders
18.13% Mutual Funds
13.00% Other Institutional Investors
68.36% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AXSM FAQ
What was Axsome Therapeutics Inc’s price range in the past 12 months?
Axsome Therapeutics Inc lowest stock price was $55.02 and its highest was $98.40 in the past 12 months.
What is Axsome Therapeutics Inc’s market cap?
Currently, no data Available
When is Axsome Therapeutics Inc’s upcoming earnings report date?
Axsome Therapeutics Inc’s upcoming earnings report date is Aug 05, 2024 which is in 17 days.
How were Axsome Therapeutics Inc’s earnings last quarter?
Axsome Therapeutics Inc released its earnings results on May 06, 2024. The company reported -$1.44 earnings per share for the quarter, missing the consensus estimate of -$1.205 by -$0.235.
Is Axsome Therapeutics Inc overvalued?
According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued.
Does Axsome Therapeutics Inc pay dividends?
Axsome Therapeutics Inc does not currently pay dividends.
What is Axsome Therapeutics Inc’s EPS estimate?
Axsome Therapeutics Inc’s EPS estimate is -$1.3.
How many shares outstanding does Axsome Therapeutics Inc have?
Axsome Therapeutics Inc has 47,495,827 shares outstanding.
What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?
Axsome Therapeutics Inc reported an EPS of -$1.44 in its last earnings report, missing expectations of -$1.205. Following the earnings report the stock price went up 1.524%.
Which hedge fund is a major shareholder of Axsome Therapeutics Inc?
Among the largest hedge funds holding Axsome Therapeutics Inc’s share is Fairmount Funds Management Llc. It holds Axsome Therapeutics Inc’s shares valued at 188M.
---
Axsome Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$121.11 (47.44% Upside)
$121.11 (47.44% Upside)
Blogger Sentiment
Bullish
AXSM Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 172.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.27%
12-Months-Change
Fundamentals
Return on Equity
-231.68%
Trailing 12-Months
Asset Growth
40.23%
Trailing 12-Months
Company Description
Axsome Therapeutics Inc
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
---
AXSM Earnings Call
Q1 2024
0:00 / 0:00
---
AXSM Stock 12 Month Forecast
Average Price Target
$121.11
▲(47.44% Upside)
Technical Analysis
Best Analysts Covering AXSM
1 Year
1 Year Success Rate
15/17 ratings generated profit
1 Year Average Return
+15.28%
reiterated a buy rating last month
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 88.24% of your transactions generating a profit, with an average return of +15.28% per trade.
---